Table 5.
Variables | Treatment | Placebo BID | PG 500 mg BID | PG 1000 mg BID | Reference range |
---|---|---|---|---|---|
Total protein (g/dL) | Before | 7.6±0.3 | 7.5±0.4 | 7.5±0.3 | 6.4–8.3 |
After | 7.6±0.3 | 7.6±0.4 | 7.7±0.4 | ||
Albumin (g/dL) | Before | 4.7±0.3 | 4.8±0.2 | 4.7±0.2 | 3.8–5.1 |
After | 4.7±0.2 | 4.7±0.2 | 4.7±0.2 | ||
A/G ratio | Before | 1.6±0.2 | 1.7±0.1 | 1.7±0.2 | |
After | 1.6±0.2 | 1.7±0.2 | 1.6±0.2 | ||
T. bilirubin (mg/dL) | Before | 1.1±0.4 | 1.0±0.2 | 0.9±0.4 | 0.1–1.2 |
After | 1.1±0.5 | 0.9±0.3 | 1.0±0.4 | ||
AST (IU/L) | Before | 24.4±10.6 | 22.2±5.5 | 21.8±4.5 | 0–40 |
After | 22.9±7.6 | 23.6±6.1 | 21.2±4.6 | ||
ALT (IU/L) | Before | 26.4±19.3 | 21.4±11.6 | 21.0±9.1 | 0–40 |
After | 24.6±12.7 | 21.5±9.7 | 19.5±6.4 | ||
ALP (IU/L) | Before | 65.9±17.3 | 79.7±21.1 | 61.5±9.8 | 30–120 |
After | 68.8±18.7 | 80.4±21.4 | 63.4±11.0 | ||
r‐GTP (IU/L) | Before | 28.6±14.1 | 24.6±12.7 | 28.2±17.7 | 0–64 |
After | 25.4±11.2 | 24.1±11.0 | 24.8±11.8 | ||
Cholesterol (mg/dL) | Before | 209.4±38.9 | 187.0±42.5 | 201.9±33.7 | 140–271 |
After | 206.8±47.0 | 188.1±25.3 | 199.6±26.3 | ||
Triglycerides (mg/dL) | Before | 144.4±111.4 | 130.4±61.1 | 145.6±82.5 | 130–220 |
After | 153.6±96.4 | 138.0±86.3 | 155.3±59.3 | ||
HDL‐Chol (mg/dL) | Before | 47.8±11.0 | 48.5±8.7 | 49.1±7.3 | 42–88 |
After | 45.3±10.5 | 49.3±10.6 | 48.1±7.1 | ||
Glucose (mg%) | Before | 91.1±7.8 | 88.9±9.3 | 91.6±5.9 | 70–115 |
After | 96.6±10.7 | 92.3±10.0 | 96.5±10.6 | ||
Creatinine (mg/dL) | Before | 1.0±0.1 | 1.0±0.1 | 1.0±0.1 | 0.4–1.5 |
After | 1.1±0.2 | 1.0±0.1 | 1.0±0.2 | ||
BUN (mg/dL) | Before | 13.7±3.7 | 13.3±2.8 | 13.7±2.5 | 5–24 |
After | 12.6±2.4 | 12.7±3.6 | 12.9±3.0 |
Data are expressed as mean±standard deviation.
A/G, albumin to globulin ratio; T. bilirubin, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; r-GTP, gamma-glutamyl transpeptidase; HDL-Chol, high-density lipoprotein cholesterol; BUN, blood urea nitrogen.